A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ALT 2074 [SYI 2074] in Subjects With Type 2 Diabetes Who Have a Haptoglobin Type 2-2 Genotype and Coronary Artery Disease
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2008
At a glance
- Drugs SYI 2074 (Primary)
- Indications Acute coronary syndromes; Coronary artery disease
- Focus Pharmacodynamics
- Sponsors Synvista Therapeutics
- 04 Jul 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jul 2007 New trial record.